Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading information in its IPO documents, which has resulted in significant stock price decline since the IPO [1][4]. Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases [2]. IPO Details - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.7 million shares at a price of $17.00 per share [2]. Allegations in the Lawsuit - The lawsuit claims that the IPO offering documents were materially false and misleading, failing to disclose critical information regarding the Phase Two and Phase Three clinical trials of Neumora's flagship therapeutic candidate, Navacaprant [3]. - Specific allegations include the amendment of trial inclusion criteria to justify the Phase Three program and the lack of adequate data in the Phase Two trials to predict outcomes accurately [3]. Stock Performance - Following the IPO, Neumora's stock price has plummeted from $17.00 per share to $1.91 per share as of February 5, 2025, representing an 88.7% decline [4].

Shares of Neumora Therapeutics (NMRA) lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, navacaprant, in a late-stage study for major depressive disorder (MDD).The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating ...

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer’s disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025 Strong financial position with $341.3 million in cash, cash equivalents and marketable securities ...

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November: Guggenheim’s Inaugural Healthcare Innovation Conference: Members of management will participate in a fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.Stifel ...

NMRA-511 was generally well-tolerated at all dose levels in Phase 1 single ascending dose / multiple ascending dose study, with no serious adverse events reported to date Several lines of evidence indicate that V1aR antagonists have therapeutic potential for reducing symptoms of agitation. Pre-clinically, multiple models have demonstrated that activating the vasopressin system with the endogenous agonist AVP modulates social-emotional, anxiety and threat-related behaviors across species. In rodents, the sel ...

Core Insights - Neumora Therapeutics has initiated a Phase 1b study for NMRA-511, targeting agitation associated with Alzheimer's disease (AD) [11][12] - NMRA-511 is a highly potent and selective antagonist of the vasopressin 1a receptor (V1aR), which is implicated in regulating aggression, stress, and anxiety responses [7][11] - The study aims to evaluate the safety, tolerability, and efficacy of NMRA-511 in both healthy elderly participants and individuals with agitation due to AD [11][12] Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain diseases, with a pipeline of seven clinical and preclinical neuroscience programs [3][11] - The company's mission is to redefine neuroscience drug development by utilizing advanced translational, clinical, and computational tools to enable precision medicine approaches [3] Clinical Study Details - The Phase 1b study consists of two parts: Part A will involve approximately 8 healthy elderly participants, while Part B will include around 88 individuals with agitation associated with dementia due to AD [11] - The primary endpoint of the study is the change from baseline to Week 8 on the Cohen-Mansfield Agitation Inventory total score [11] Market Context - Approximately 7 million people in the U.S. currently live with Alzheimer's disease, with projections indicating this number could exceed 13 million by 2050 [13] - Behavioral symptoms, particularly agitation, affect about 70% of individuals with AD, leading to significant disability and caregiver stress [13] - Currently, there is only one approved treatment for agitation in AD, which carries a black box warning for increased mortality in elderly patients, highlighting a substantial unmet medical need [13]

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consist ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) ...

Neumora Therapeutics (NASDAQ:NMRA) just reported results for the first quarter of 2024.Neumora Therapeutics reported earnings per share of -34 cents. This met the analyst estimate for EPS of -34 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analys ...

EXHIBIT 99.1 Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents an ...